Antibody gives relief from hay fever

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

A clinical trial has shown an artificial antibody to give ‘substantial’ relief to hay fever sufferers.

The trial involved 536 patients aged between 12 and 75 years who were affected by ragweed pollen. The participants were injected with the antibody “omalizumab”*  or a placebo.  Those injected with the antibody had far fewer of the usual symptoms and reported to have less time off work and fewer visits to the doctor as a result relief from hay fever.

Omalizumab is from the family of ‘monoclonal’ antibodies which are a fairly new class of drug. They are being developed for a range of conditions including cancer and organ transplant rejection.

This is one of the first times a monoclonal antibody has been trialed with a chronic, non life-threatening disease.  It will now be interesting to compare omalizumab with standard treatments (such as antihistamines) and to see if it would be effective in  treating asthma.

To read the full article, click here.

*Omalizumab is a monoclonal antibody which blocks the action of a molecule called immunoglobulin E (IgE), the major culprit behind allergic conditions like hayfever. IgE, which is a natural antibody, triggers symptoms like streaming eyes, runny nose, and sneezing because it is key to the inflammatory process.

More To Explore

Plastic vs Glass

In recent years we have seen a growth in zero waste, more conscious living and a general move towards sustainability and reduction in unnecessary packaging. With this,

Get in touch

Please send me a weekly email with the pollen forecast and helpful tips about managing allergies:
Your personal data will be used to process your order, support your experience throughout this website, and for other purposes described in our privacy policy.

HayMax™ Ltd
Postern Piece Farm, Ampthill,
Bedford, MK45 2EX
E-mail : [email protected]
Tel : 01525 406600
© HayMax™ Ltd 2020.